BACKGROUND: Preterm very-low-birth-weight (VLBW) infants weighing <1.5 kg at birth develop anemia, often requiring multiple red blood cell transfusions (RBCTx). Because laboratory blood loss is a primary cause of anemia leading to RBCTx in VLBW infants, our purpose was to simulate the extent to which RBCTx can be reduced or eliminated by reducing laboratory blood loss in combination with pharmacodynamically optimized erythropoietin (Epo) treatment. METHODS: Twenty-six VLBW ventilated infants receiving RBCTx were studied during the first month of life. RBCTx simulations were based on previously published RBCTx criteria and data-driven Epo pharmacodynamic optimization of literature-derived RBC life span and blood volume data corrected for phlebotomy loss. RESULTS: Simulated pharmacodynamic optimization of Epo administration and reduction in phlebotomy by ≥ 55% predicted a complete elimination of RBCTx in 1.0-1.5 kg infants. In infants <1.0 kg with 100% reduction in simulated phlebotomy and optimized Epo administration, a 45% reduction in RBCTx was predicted. The mean blood volume drawn from all infants was 63 ml/kg: 33% required for analysis and 67% discarded. CONCLUSION: When reduced laboratory blood loss and optimized Epo treatment are combined, marked reductions in RBCTx in ventilated VLBW infants were predicted, particularly among those with birth weights >1.0 kg.
BACKGROUND: Preterm very-low-birth-weight (VLBW) infants weighing <1.5 kg at birth develop anemia, often requiring multiple red blood cell transfusions (RBCTx). Because laboratory blood loss is a primary cause of anemia leading to RBCTx in VLBW infants, our purpose was to simulate the extent to which RBCTx can be reduced or eliminated by reducing laboratory blood loss in combination with pharmacodynamically optimized erythropoietin (Epo) treatment. METHODS: Twenty-six VLBW ventilated infants receiving RBCTx were studied during the first month of life. RBCTx simulations were based on previously published RBCTx criteria and data-driven Epo pharmacodynamic optimization of literature-derived RBC life span and blood volume data corrected for phlebotomy loss. RESULTS: Simulated pharmacodynamic optimization of Epo administration and reduction in phlebotomy by ≥ 55% predicted a complete elimination of RBCTx in 1.0-1.5 kg infants. In infants <1.0 kg with 100% reduction in simulated phlebotomy and optimized Epo administration, a 45% reduction in RBCTx was predicted. The mean blood volume drawn from all infants was 63 ml/kg: 33% required for analysis and 67% discarded. CONCLUSION: When reduced laboratory blood loss and optimized Epo treatment are combined, marked reductions in RBCTx in ventilated VLBW infants were predicted, particularly among those with birth weights >1.0 kg.
Authors: Aryeh Shander; Axel Hofmann; Sherri Ozawa; Oliver M Theusinger; Hans Gombotz; Donat R Spahn Journal: Transfusion Date: 2009-12-09 Impact factor: 3.157
Authors: John A Widness; Ashima Madan; Ligia A Grindeanu; M Bridget Zimmerman; David K Wong; David K Stevenson Journal: Pediatrics Date: 2005-05 Impact factor: 7.124
Authors: Edward F Bell; Ronald G Strauss; John A Widness; Larry T Mahoney; Donald M Mock; Victoria J Seward; Gretchen A Cress; Karen J Johnson; Irma J Kromer; M Bridget Zimmerman Journal: Pediatrics Date: 2005-06 Impact factor: 7.124
Authors: Sandra E Juul; Ronald J McPherson; Larry A Bauer; Kelly J Ledbetter; Christine A Gleason; Dennis E Mayock Journal: Pediatrics Date: 2008-08 Impact factor: 7.124
Authors: G J Levy; R G Strauss; H Hume; L Schloz; M A Albanese; J Blazina; A Werner; C Sotelo-Avila; C Barrasso; V Blanchette Journal: Pediatrics Date: 1993-03 Impact factor: 7.124
Authors: E Henry; R D Christensen; M J Sheffield; L D Eggert; P D Carroll; S D Minton; D K Lambert; S J Ilstrup Journal: J Perinatol Date: 2014-09-25 Impact factor: 2.521